SLC5A2 and diabetic kidney disease: The latest research has revealed the key role of intestinal flora imbalance in DKD and potential intervention strategies: SGLT2 inhibitors (such as dapagliflozin) can delay the progress of DKD by regulating bile acid metabolism spectrum, enhancing antioxidant capacity, and dynamically improving the structure of intestinal flora (71).